Drug Profile


Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Preregistration Churg-Strauss syndrome
  • Phase III Chronic obstructive pulmonary disease; Hypereosinophilic syndrome; Nasal polyps
  • Phase II Atopic dermatitis
  • No development reported Eosinophilic oesophagitis

Most Recent Events

  • 25 Jul 2017 GlaxoSmithKline plans a phase III trial for Hypereosinophilic syndrome (In adolescents, In adults, In the elderly) in Argentina, Belgium, Brazil, Mexico, Russia and USA (EudraCT2017-000184-32)
  • 28 Jun 2017 Preregistration for Churg-Strauss syndrome (Adjunctive treatment) in USA (SC)
  • 28 Jun 2017 GlaxoSmithKline announces intention to submit regulatory filings in other countries for Churg-Strauss syndrome in 2017 and 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top